文献速递预防保健、筛查与疫苗老年与多病共存

BA.4-5或BA.1二价mRNA加强疫苗的安全性:全国性队列研究

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study.
PubMed 文献 · BMJ · 2023-07-25

丹麦全国性队列研究纳入2 225 567名≥50岁已接种三剂新冠疫苗的成人,评估第四剂奥密克戎适应性二价mRNA疫苗与27种不良事件住院就诊率的关系。接种后28天内未发现任何不良事件风险显著增加,按年龄、性别或疫苗类型分析结果一致,但事后分析发现心肌炎信号(女性中具统计学显著性,病例极少)。

要点

  • 第四剂二价mRNA疫苗后28天内27种不良事件住院率未显著增加。
  • 缺血性心脏事件发生率比0.95(95%CI 0.87-1.04),无显著升高。
  • 事后分析发现心肌炎信号,女性中具统计学显著性但病例极少。

核心结论

  • ≥50岁成人以二价mRNA疫苗作为第四剂新冠加强针,未与27种不良事件风险增加相关。

研究设计与样本

  • 主要比较第四剂二价mRNA疫苗接种后28天主要风险期与第三或第四剂接种后第29天起的参照期的不良事件住院就诊率。

主要发现

  • 1 740 417名成人(平均年龄67.8岁,标准差10.7岁)以二价mRNA疫苗作为第四剂接种。
  • 第四剂接种后28天内27种不良结局均未显示统计学显著升高的发生率。
  • 缺血性心脏事件发生率比0.95(95%CI 0.87-1.04),风险期672例 vs 参照期9992例。
  • 脑血管梗死发生率比0.95(95%CI 0.87-1.05),风险期644例 vs 参照期9687例。
  • 按年龄、性别或疫苗类型分析及替代分析方法均未改变结果;事后分析检出心肌炎信号(女性中具统计学显著性),但结局罕见且基于少量病例。

临床怎么用

  • 为≥50岁成人接种第四剂二价mRNA新冠加强针时,可参考本队列结果向患者说明28天内27种不良事件风险未见显著增加。
  • 对心肌炎事后信号应保持关注,尤其女性,但需注意其基于极少病例且为事后分析。

局限性

  • 心肌炎信号来自事后分析,结局罕见且基于少量病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between the omicron adapted bivalent mRNA covid-19 booster vaccines received as a fourth dose and risk of adverse events. DESIGN: Nationwide cohort study. SETTING: Denmark. PARTICIPANTS: 2 225 567 adults aged ≥50 years who received three covid-19 vaccine doses during the study period, 1 January 2021 to 10 December 2022. MAIN OUTCOME MEASURES: The main outcome measure was rates of hospital visits for 27 different adverse events in a 28 day main risk period after vaccination with a bivalent omicron adapted mRNA booster vaccine as a fourth dose compared with reference period rates from day 29 after the third or fourth vaccine dose and onward. RESULTS: 1 740 417 adults (mean age 67.8 years, standard deviation 10.7 years) received a bivalent mRNA vaccine as a fourth dose. Fourth dose vaccination with a bivalent mRNA vaccine was not associated with a statistically significant increased rate of any of the 27 adverse outcomes within 28 days (eg, incidence rate ratio of 0.95, 95% confidence interval of 0.87 to 1.04 for ischaemic cardiac events based on 672 v 9992 events during the compared 28 day risk and reference period, respectively), nor when analysed according to age, sex, or vaccine type, or when using alternative analytical approaches. However, post hoc analysis detected signals for myocarditis (statistically significant in female participants), although the outcome was rare and findings were based on few cases. No risk of cerebrovascular infarction was found (incidence rate ratio 0.95, 95% confidence interval 0.87 to 1.05; 644 v 9687 events). CONCLUSIONS: The use of bivalent mRNA vaccines as a fourth vaccine dose against covid-19 was not associated with an increased risk of 27 different adverse events in adults aged ≥50 years.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Andersson NW, Thiesson EM, Hansen JV, et al. Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study. BMJ. 2023. PMID: 37491031. doi:10.1136/bmj-2023-075015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。